The Cancer Control (CaC) Research Program is a newly restructured transdisciplinary program that serves as the hub for cancer control and population science research within the University of New Mexico Cancer Center (UNMCC) and the State of New Mexico (NM), our catchment area. The Program's overall goal is to reduce cancer incidence, morbidity, and mortality, particularly in the unique multiethnic and underserved populations of NM. Disparities research is a cross-cutting theme that fosters scientific focus and synergy across the research areas. Through vigorous strategic program planning and evaluation, recruitment of 9 new investigators to enhance expertise in molecular epidemiology and behavioral/community intervention, and guidance of the UNMCC External Advisory Committee, the CaC Program is now focused on three areas of cancer research: 1) Risk Prediction and Risk Reduction; 2) Screening; and 3) Post-Diagnosis Outcomes and Survivorship. Unique scientific strengths include research addressing disparities (geographic, race/ethnic, socioeconomic, medically underserved), particularly in etiologic, outcome, and intervention studies in Hispanics. By drawing on established and new partnerships, the Program is also building research that addresses American Indian cancer disparities and priorities identified by NM Tribes, Pueblos, and Indian Nations. Major scientific accomplishments in Risk Prediction and Risk Reduction include the identification of social, lifestyle, and genetic factors associated with lung cancer risk; gene-environment interactions in melanoma risk; and development and dissemination of a novel telehealth strategy for the prevention of hepatocellular cancer. In Screening, members have developed a statewide surveillance program of screening and diagnosis for cervical pre-cancer and cancer that informs real- world cervical cancer prevention through human papilloma virus (HPV) vaccination, screening practice and outcomes. Members have also identified barriers to use of early detection tests in colorectal cancer and have developed strategies to overcome these barriers to improve screening in underserved populations. In Post- Diagnosis Outcomes and Survivorship, members have identified factors that contribute to disparities in post- treatment outcomes and survivorship in endometrial and breast cancer and are developing interventions. Led by Linda Cook, Ph.D. and Anita Kinney, Ph.D., RN, the CaC Program is comprised of 28 members (19 full and 9 associate) from 7 UNM schools and departments, the Lovelace Respiratory Institute, and the Indian Health Service Unit of the Centers for Disease Control whose work is supported by $19,276,863 million in annual direct cost funding, of which $15,429,911 million is peer-reviewed and $3,137,820 million is from NCI as of 9/1/2014. The discoveries made in this Program have resulted 294 publications, of which 19% are intra-programmatic collaborations and 16% are inter-programmatic collaborations; with a total UNMCC and external collaborative publication level of 30% and 80%, respectively.

Public Health Relevance

OVERALL COMPONENT: THE UNIVERSITY OF NEW MEXICO CANCER CENTER PROJECT NARRATIVE Designated as one of the nation's National Cancer Institute Cancer Centers since 2005, the University of New Mexico Cancer Center is a cancer treatment, research, and education and training center that applies the scientific expertise of its investigators to those cancers that have high incidence, mortality, or disparity in the multiethnic and underserved populations of New Mexico. The Center is a hub for promoting discovery through its research, education and training, clinical care, statewide outreach programs and networks for community participatory research. The Center connects scientists, healthcare professionals, and communities to translate its discoveries to cancer clinical trials, and cancer control and behavioral interventions that reduce the cancer burden of New Mexico and serve as a national model. The goal of the Center is to assure that all of the people in New Mexico, its catchment area, have access to high quality cancer care and collaborate in and benefit from advances in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA118100-11S5
Application #
9133656
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
2005-09-26
Project End
2017-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
11
Fiscal Year
2015
Total Cost
$172,654
Indirect Cost
$42,654
Name
University of New Mexico Health Sciences Center
Department
Pathology
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Guo, Yan; Yu, Hui; Wang, Jing et al. (2018) The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes (Basel) 9:
Hatch, Ellen W; Geeze, Mary Beth; Martin, Cheyenne et al. (2018) Variability of PD-L1 expression in mastocytosis. Blood Adv 2:189-199
Frerich, Candace A; Brayer, Kathryn J; Painter, Brandon M et al. (2018) Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget 9:7341-7358
Kinney, Anita Y; Howell, Rachel; Ruckman, Rachel et al. (2018) Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial. Contemp Clin Trials 73:123-135
Tasnim, Humayra; Fricke, G Matthew; Byrum, Janie R et al. (2018) Quantitative Measurement of Naïve T Cell Association With Dendritic Cells, FRCs, and Blood Vessels in Lymph Nodes. Front Immunol 9:1571
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Castleman, Moriah J; Pokhrel, Srijana; Triplett, Kathleen D et al. (2018) Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by ?-Hemolysin. J Immunol 200:657-668
Barton, Matthias; Filardo, Edward J; Lolait, Stephen J et al. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol 176:4-15
Prossnitz, Eric R (2018) GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol 176:73-81
Perez, Dominique R; Nickl, Christian K; Waller, Anna et al. (2018) High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. SLAS Discov 23:732-741

Showing the most recent 10 out of 344 publications